# EDGAR Filing Document

**Accession Number:** 0001755237
**File Stem:** 0001193125-25-142765
**Filing Date:** 2025-6
**Character Count:** 6400
**Document Hash:** cdb7214410ce4c6d66a23b50a39f6ac9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-142765.hdr.sgml**: 20250618

**ACCESSION NUMBER**: 0001193125-25-142765

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250616

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250618

**DATE AS OF CHANGE**: 20250618

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cyclerion Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001755237
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 831895370
- **STATE OF INCORPORATION:** MA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38787
- **FILM NUMBER:** 251057490

**BUSINESS ADDRESS:**
- **STREET 1:** 301 BINNEY STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** 617-621-7722

**MAIL ADDRESS:**
- **STREET 1:** 301 BINNEY STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): June 18, 2025 (June 16, 2025)

## CYCLERION THERAPEUTICS, INC.

#### (Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Massachusetts** | **001-38787** | **83-1895370** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification Number)** |

---

#### 245 First Street, 18th Floor

#### Cambridge, Massachusetts 02142

#### (Address of principal executive offices, including Zip Code)

#### Registrant's telephone number, including area code: (857) 327-8778
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **Symbol(s)** | **Name of each exchange**<br> **on which registered** |
| Common Stock, no par value | CYCN | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| Item 5.07 | Submission of Matters to a Vote of Security Holders.  |

---

At the Annual Meeting of Shareholders of Cyclerion Therapeutics, Inc. (the "Company") held on June 16, 2025, as contemplated by the Company's definitive proxy material for the meeting, certain matters were submitted to a vote of shareholders. The following tables summarize the results of voting with respect to each matter:

1. Election of Directors:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | For | Against | Abstain | Broker<br>Non-Votes |
|  Errol De Souza, Ph.D. | 1332504 | 64573 | 44 | 743285 |
|  Regina Graul, Ph.D. | 1334531 | 62543 | 47 | 743285 |
|  Peter M. Hecht, Ph.D. | 1323702 | 73376 | 43 | 743285 |
|  Steven Hyman, M.D. | 1328384 | 68692 | 45 | 743285 |
|  Michael Higgins | 1334201 | 62876 | 44 | 743285 |
|  Dina Katabi, Ph.D. | 1334243 | 62798 | 80 | 743285 |

---

2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025:

<u> For</u> <u> Against</u> <u> Abstain</u> <br> 2,072,684 57,547 147

3. The compensation of the Company's named executive officers as disclosed in the Proxy Statement was approved in an advisory vote, as set forth below:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| 1312697 | 78221 | 6203 | 743285 |

---

---

| | |
|:---|:---|
| 4 | The frequency of the future votes on compensation of the Company's named executive officers as disclosed in the Proxy Statement was approved in an advisory vote, as set forth below:  |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| One Year | Two Years | Three Years | Abstain | Broker Non-Votes |
| 827809 | 164 | 562965 | 6183 | 0 |

---

5. To approve a proposal to adjourn the Annual Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of either the Election of Directors Proposal or the Auditor Ratification Proposal:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| 2036703 | 84719 | 18984 | 0 |

---

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

---

| | |
|:---|:---|
| Exhibit<br>No. | Description |
| 104 | Cover Page Interactive Data File |

---

------

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | Cyclerion Therapeutics, Inc. | Cyclerion Therapeutics, Inc. |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dated: June 18, 2025 | By: | /s/ Regina Graul |
|  | Name: | Regina Graul |
|  | Title: | President and Chief Executive Officer |

---